Abstract
Bronchopulmonary dysplasia (BPD) is the major cause of chronic lung disease and morbidity in preterm infants. Since it was first described fifty years ago, the epidemiology, pathogenesis, and treatment for BPD has changed dramatically. This review summarizes these changes and the clinical outcomes for infants diagnosed with BPD.
Keywords:
Glucocorticoids; Oxygenation; Preterm infants; Surfactant; Ventilation.
Copyright © 2017. Published by Elsevier Ltd.
MeSH terms
-
Bronchopulmonary Dysplasia / epidemiology
-
Bronchopulmonary Dysplasia / etiology
-
Bronchopulmonary Dysplasia / physiopathology
-
Bronchopulmonary Dysplasia / therapy*
-
Chronic Disease
-
Continuous Positive Airway Pressure
-
Glucocorticoids / therapeutic use
-
Humans
-
Infant
-
Infant, Extremely Premature
-
Infant, Newborn
-
Infant, Premature
-
Lung Diseases / epidemiology
-
Lung Diseases / etiology
-
Lung Diseases / physiopathology
-
Lung Diseases / therapy
-
Oxygen Inhalation Therapy*
-
Prenatal Care
-
Pulmonary Surfactants / therapeutic use*
-
Respiration, Artificial*
-
Respiratory Distress Syndrome, Newborn / complications
Substances
-
Glucocorticoids
-
Pulmonary Surfactants
Supplementary concepts
-
Respiratory Distress Syndrome In Premature Infants